RxDoctor Payments Data

Thomas Oliver, MD

Cardiovascular Disease · Bellingham, WANPI 1164471884

Payments from drug & device makers

$1,754in general payments, 2019–2025

Across 25 payments — averaging $70.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • E.r. Squibb & Sons, L.L.C.$189
  • Boston Scientific$96
  • Novartis$31
  • AstraZeneca$27
  • Irhythm Technologies, Inc.$24
  • plus $115 from 6 others

What the payments were for

  • Travel & lodging$1,07161%
  • Food & beverage$68339%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,754 in reported general payments places this provider in the 60th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$184,887
Medicare patients
1,471
Services billed
5,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban230$280,274
XareltoRivaroxaban67$87,997
EntrestoSacubitril/Valsartan24$39,882
JardianceEmpagliflozin13$15,676
Repatha SureclickEvolocumab15$8,212
Dabigatran EtexilateDabigatran Etexilate Mesylate23$7,883
Metoprolol Succinate505$7,607
PradaxaDabigatran Etexilate Mesylate17$4,663
Losartan Potassium308$4,347
Carvedilol434$4,131
Ranolazine ErRanolazine39$2,851
Torsemide119$2,836
Atorvastatin Calcium172$2,410
Diltiazem 24hr Er (Cd)Diltiazem Hcl86$2,405
Rosuvastatin Calcium110$2,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$19$87,99767 claims
NovartisEntresto$31$39,88224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Bellingham

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →